Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
Department of Dermatology, University of New South Wales, Sydney, New South Wales, Australia.
Dermatol Ther. 2020 Nov;33(6):e13956. doi: 10.1111/dth.13956. Epub 2020 Jul 25.
Bullous pemphigoid (BP) is the most common autoimmune blistering disease with subepidermal involvement, typically affecting the elderly. It has spontaneous remissions and exacerbations with significant morbidity. A novel coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the new universal coronavirus disease 2019 (COVID-19) pandemic. The pandemic made concerns, especially about immunosuppressive therapy. In this article, we reviewed the management of BP in the COVID-19 pandemic era. The data about the best management of autoimmune bullous diseases like BP, during the outbreak of COVID-19, are evolving and updated every day.
大疱性类天疱疮（BP）是最常见的自身免疫性表皮下水疱病，通常影响老年人。它具有自发性缓解和加重，发病率高。一种新型冠状病毒称为严重急性呼吸综合征冠状病毒 2（SARS-CoV-2），是造成新型普遍的 2019 年冠状病毒病（COVID-19）大流行的原因。大流行引起了人们的关注，特别是对免疫抑制治疗的关注。在本文中，我们回顾了 COVID-19 大流行期间 BP 的管理。关于 COVID-19 爆发期间 BP 等自身免疫性大疱性疾病的最佳治疗方法的数据每天都在不断发展和更新。
